The need for comprehensive and multidisciplinary training in substandard and falsified medicines for pharmacists [PDF]
BMJ Global Health, 2019 The global burden of substandard and falsified (SF) medicines is only beginning to be better understood. A 2017 literature review by WHO estimated a 10.5% observed failure rate of the analysed medical product samples in low-income and middle-income countries.1 The report also estimated that between 72 430 and 169 271 deaths in children under 5 with ...
Veronika J Wirtz +4 more
doaj +5 more sources
Medicine Access @ Point of Care, 2022 Substandard and falsified (SF) medicines are a global health challenge with the World Health Organization (WHO) estimating that 1 in 10 of medicines in low- and middle-income countries (LMICs) are SF. Antimicrobials (i.e.
Bahijja Tolulope Abraham +1 more
exaly +4 more sources
Improving access to medicines to reduce marketing and use of substandard and falsified medicines in Africa: Scoping review [PDF]
J Med AccessBackground: Both constrained access to essential medicines and combatting marketing of substandard and falsified (SF) medicines are unmet health sector goals in Africa. Objective: To answer the question of how improved access can ...
Majid Davari +2 more
exaly +4 more sources
Substandard and falsified medicine recalls in the legitimate supply chain: a systematic review of evidence [PDF]
BMJ OpenObjectives To compare international substandard and falsified (SF) medicine recall trends from published research papers based on governmental databases, summarise the extent of the problem in the legitimate supply chain, and identify ways to manage the ...
Bernard D Naughton, Izabella Fryze
doaj +4 more sources
The hidden peril: Ecuador's struggle with substandard and falsified medicines [PDF]
Frontiers in Public HealthJorge Vasconez-Gonzalez +2 more
doaj +4 more sources
Substandard, falsified and unregistered medicines in Latin America, 2017-2018 [PDF]
Revista Panamericana de Salud Pública, 2020 Objective. To assess all the incidents of substandard, falsified and unregistered medicines in 2017 and 2018 in Latin America, determining the types of products affected, stages of the supply chain in which incidents were detected, quality deviations ...
Robin Rojas-Cortés
doaj +3 more sources
Substandard and falsified medicines in Africa: healthcare systems challenges, supply chain issues, regulatory challenges and strategies to increase access to quality medicines [PDF]
Frontiers in PharmacologyAfrica is a unique continent due to high disease burden for both communicable and non-communicable diseases, attracting large-scale distribution of medicines to tackle public health issues.
Billy Chabalenge +3 more
doaj +2 more sources
Substandard and falsified medicine screening technologies [PDF]
AAPS Open, 2019 Substandard and falsified medicine screening technologies are invaluable tools for post-marketing surveillance of medicine quality, particularly in low- and middle-income countries.
Lukas Roth +2 more
doaj +2 more sources
Surveillance for substandard and falsified medicines by local faith-based organizations in 13 low- and middle-income countries using the GPHF Minilab [PDF]
Scientific Reports, 2022 This study evaluates the use of the Global Pharma Health Fund (GPHF) Minilab for medicine quality screening by 16 faith-based drug supply organizations located in 13 low- and middle-income countries. The study period included the year before the COVID-19
Gesa Gnegel +4 more
doaj +2 more sources
Identification of Substandard and Falsified Medicines: Influence of Different Tolerance Limits and Use of Authenticity Inquiries. [PDF]
Am J Trop Med Hyg, 2021 ABSTRACTSubstandard and falsified medicines have severe public health and socioeconomic effects, especially in low- and middle-income countries. The WHO has emphasized the need for reliable estimates of the prevalence of such medicines to efficiently respond to this problem.
Hauk C, Hagen N, Heide L.
europepmc +4 more sources